RxDoctor Payments Data

Gregory Kelly, MD

Cardiovascular Disease · Queensbury, NYNPI 1982606984

Payments from drug & device makers

$2,710in general payments, 2019–2025

Across 158 payments — averaging $17.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$507
  • Boehringer Ingelheim$343
  • E.r. Squibb & Sons, L.L.C.$262
  • Baxter Healthcare$202
  • Johnson & Johnson$166
  • AstraZeneca$157
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,63597%
  • Education$753%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,710 in reported general payments places this provider in the 55th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$90,429
Medicare patients
1,182
Services billed
2,268

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban302$324,872
ArcalystRilonacept12$254,865
EntrestoSacubitril/Valsartan90$143,590
Repatha SureclickEvolocumab63$67,395
XareltoRivaroxaban34$41,427
BrilintaTicagrelor31$37,618
JardianceEmpagliflozin25$29,343
Praluent PenAlirocumab30$17,528
Repatha SyringeEvolocumab17$10,306
Metoprolol Succinate470$8,830
Dabigatran EtexilateDabigatran Etexilate Mesylate17$5,069
Ranolazine ErRanolazine23$3,517
Rosuvastatin Calcium188$3,291
Ezetimibe103$2,915
Atorvastatin Calcium254$2,589

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$152$324,872302 claims
Kiniksa Pharmaceuticals International, PLCArcalyst$22$254,86512 claims
NovartisEntresto$507$143,59090 claims
Johnson & JohnsonXarelto$166$41,42734 claims
AstraZenecaBrilinta$157$37,61831 claims
Boehringer IngelheimJardiance$343$29,34325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Queensbury

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →